| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/CVR/CVT006 |
| P698 | PubMed publication ID | 23341576 |
| P2093 | author name string | David Fedida | |
| Joseph J Lynch | |||
| Klaus Matschke | |||
| John K Gibson | |||
| Ursula Ravens | |||
| Erich Wettwer | |||
| Torsten Christ | |||
| Nadiia Rozmaritsa | |||
| Michael Knaut | |||
| Marc Pourrier | |||
| Sebastian Endig | |||
| P433 | issue | 1 | |
| P921 | main subject | Atrial Fibrillation | Q815819 |
| P304 | page(s) | 145-154 | |
| P577 | publication date | 2013-01-22 | |
| P1433 | published in | Cardiovascular Research | Q4642329 |
| P1476 | title | The new antiarrhythmic drug vernakalant: ex vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillation | |
| P478 | volume | 98 |
| Q38139281 | Antiarrhythmic drugs 2013: state of the art. |
| Q42287521 | Atrial Fibrillation Dynamics and Ionic Block Effects in Six Heterogeneous Human 3D Virtual Atria with Distinct Repolarization Dynamics. |
| Q38111636 | Atrial selectivity of antiarrhythmic drugs |
| Q39785206 | Atrial-like cardiomyocytes from human pluripotent stem cells are a robust preclinical model for assessing atrial-selective pharmacology. |
| Q41029009 | Balance between sodium and calcium currents underlying chronic atrial fibrillation termination: An in silico intersubject variability study. |
| Q90215315 | Cardiovascular pharmacology of K2P17.1 (TASK-4, TALK-2) two-pore-domain K+ channels |
| Q92480289 | Generating ring-shaped engineered heart tissues from ventricular and atrial human pluripotent stem cell-derived cardiomyocytes |
| Q57283285 | German Cardiac Society Working Group on Cellular Electrophysiology state-of-the-art paper: impact of molecular mechanisms on clinical arrhythmia management |
| Q33906188 | Human iPSC-derived cardiomyocytes cultured in 3D engineered heart tissue show physiological upstroke velocity and sodium current density. |
| Q55328806 | Inhibition of Small Conductance Calcium-Activated Potassium (SK) Channels Prevents Arrhythmias in Rat Atria During β-Adrenergic and Muscarinic Receptor Activation. |
| Q35231876 | Inter-subject variability in human atrial action potential in sinus rhythm versus chronic atrial fibrillation |
| Q43228224 | Multi-channel blockers for treatment of atrial fibrillation: an effective strategy? |
| Q39257194 | Refractoriness in human atria: Time and voltage dependence of sodium channel availability. |
| Q38103541 | Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update |
| Q42658517 | Termination of Vernakalant-Resistant Atrial Fibrillation by Inhibition of Small-Conductance Ca2+-Activated K+ Channels in Pigs |
| Q38205011 | Vernakalant for the conversion of atrial fibrillation: the new kid on the block? |
| Q92003766 | Vernakalant in Atrial Fibrillation: A Relatively New Weapon in the Armamentarium Against an Old Enemy |
| Q50690847 | [New developments in the antiarrhythmic therapy of atrial fibrillation]. |
Search more.